Ajanta Pharma net up 20 percent in Q4

Top Stories

»	49% Indian startups now from tier 2, 3 cities: Jitendra Singh
»	'India ranks 3rd in global startup ecosystem & number of unicorns'
»	Tripura exported over 9K tonnes of pineapples in 2 years
»	CPI inflation eases to 6.71% in July, IIP falls to 12.3%
»	Rupee depreciates 12 paise to close at 79.64 against US dollar

SME Times News Bureau | 09 May, 2015
Drug major Ajanta Pharma Ltd has posted Rs.84 crore net profit for fourth quarter of 2014-15, registering 20 percent year-on-year (YoY) on standalone basis.

In a regulatory filing to the stock exchanges on Friday, the city-based specialty focused pharmaceutical formulation major said standalone revenue for Q4 grew 19 percent YoY to Rs.369 crore.

"Ebitda (earnings before income tax, depreciation and amortization grew 25 percent YoY to Rs.141 crore, while exports accounted for 67 percent of the revenue for the quarter," the company said in a statement.

For the entire fiscal, net profit grew 39 percent YoY to Rs.306 crore and revenue from operations grew 22 percent YoY to Rs.1,356 crore on standalone, while Ebitda growth was 37 percent YoY to Rs.473 crore. Exports contributed 63 percent of the total operating income.

On consolidated basis, net profit for the fiscal grew 32 percent YoY to Rs.310 crore and revenue 23 percent YoY to Rs.1,481 crore, while Ebitda was 37 percent YoY to Rs.505 crore. Exports were 66 percent of the total income.

"All our businesses continue to perform in-line with our expectations. We are committed and focused on present geographies and therapeutic segments to drive above industry growth consistently," Ajanta managing director Yogesh M. Agarwal said.

In the therapeutic segments, the company posted robust growth of 37percent YoY in cardiology, 31 percent YoY in ophthalmology, 11 percent in dermatotogy and 27 percent in pain management.